Zobrazeno 1 - 10
of 159
pro vyhledávání: '"Fumiaki Kobayashi"'
Autor:
Shunpei Iida, MD, Fumiaki Kobayashi, MD, Ryutaro Kawano, MD, Kazuo Saita, MD, PhD, Satoshi Ogihara, MD, PhD
Publikováno v:
Radiology Case Reports, Vol 16, Iss 4, Pp 938-941 (2021)
Vertebral hemangiomas are common benign tumors that are mostly asymptomatic and are discovered incidentally. Only 0.9–1.2% of all vertebral hemangiomas, termed aggressive vertebral hemangiomas, expand to cause pain and neural compression. We presen
Externí odkaz:
https://doaj.org/article/f2b5da2304e74872bd9f19fe1dbb20b4
Autor:
Kunihiko Kato, Fumiaki Kobayashi, Yunzi Xin, Sohei Nakagawa, Harumitsu Nishikawa, Takashi Shirai
Publikováno v:
Materials Research Express, Vol 9, Iss 2, p 020007 (2022)
Ceramic catalyst without precious metals and rare-earth elements is a promising technology for removing volatile organic compounds (VOC) produced in the manufacturing process to feasibly solve worldwide health and environmental problems. We first inv
Externí odkaz:
https://doaj.org/article/bf92d85640244416b003dc1de316139f
Autor:
Funda Meric-Bernstam, Ian Krop, Dejan Juric, Takahiro Kogawa, Erika Hamilton, Alexander I. Spira, Toru Mukohara, Takuya Tsunoda, Senthil Damodaran, Jonathan Greenberg, Wen Gu, Fumiaki Kobayashi, Hong Zebger-Gong, Yui Kawasaki, Rie Wong, Aditya Bardia
Publikováno v:
Cancer Research. 83:PD13-08
Background: Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate (ADC) consisting of a humanized anti-TROP2 IgG1 monoclonal antibody covalently linked to a highly potent topoisomerase I (Topo I) inhibitor payload via a stable, tumor-select
Autor:
Aditya Bardia, Ian Krop, Funda Meric-Bernstam, Anthony W. Tolcher, Toru Mukohara, Aaron Lisberg, Toshio Shimizu, Erika Hamilton, Alexander I. Spira, Kyriakos P. Papadopoulos, Jonathan Greenberg, Wen Gu, Fumiaki Kobayashi, Hong Zebger-Gong, Yui Kawasaki, Rie Wong, Takahiro Kogawa
Publikováno v:
Cancer Research. 83:P6-10
Background: Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate (ADC) consisting of a humanized anti-TROP2 IgG1 mAb covalently linked to a highly potent topoisomerase I (Topo I) inhibitor payload via a stable, tumor selective, tetrapeptid
Autor:
Ian Krop, Dejan Juric, Toshio Shimizu, Anthony Tolcher, Alexander Spira, Toru Mukohara, Aaron E. Lisberg, Takahiro Kogawa, Kyriakos P. Papadopoulos, Erika Hamilton, Senthil Damodaran, Jonathan Greenberg, Wen Gu, Fumiaki Kobayashi, Ferdinand Guevara, Takahiro Jikoh, Yui Kawasaki, Funda Meric-Bernstam, Aditya Bardia
Publikováno v:
Cancer Research. 82:GS1-05
Background: Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate consisting of a humanized anti-TROP2 IgG1 monoclonal antibody conjugated to a potent topoisomerase I inhibitor payload via a stable tetrapeptide-based cleavable linker. Preli
Publikováno v:
Radiology Case Reports
Radiology Case Reports, Vol 16, Iss 4, Pp 938-941 (2021)
Radiology Case Reports, Vol 16, Iss 4, Pp 938-941 (2021)
Vertebral hemangiomas are common benign tumors that are mostly asymptomatic and are discovered incidentally. Only 0.9–1.2% of all vertebral hemangiomas, termed aggressive vertebral hemangiomas, expand to cause pain and neural compression. We presen
Autor:
Michael S. Gordon, Andrew J. Wagner, Fumiaki Kobayashi, Hamim Zahir, Cynthia Zamora, Roohi Gajee, Jonathan Greenberg, Qiang Wang, Hani M. Babiker
Publikováno v:
Journal of Clinical Pharmacology
Pexidartinib is approved for treatment of adults with symptomatic tenosynovial giant cell tumor. In vitro data showed pexidartinib's potential to inhibit and induce cytochrome P450 (CYP) 3A, inhibit CYP2C9, CYP2C19 and P‐glycoprotein (P‐gp). Here
Publikováno v:
Clinical Pharmacology in Drug Development. 9:709-718
This phase 1 single-center, single-dose, double-dummy, placebo-controlled, 4-period and 4-sequence crossover study assessed the potential of esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker used to treat hypertension, to affect ca
Autor:
Curtis Rambaran, Fumiaki Kobayashi, Penny McPhillips, Tharin Limsakun, Alexander G. Vandell, Jarema Kochan, Victor Dishy, Jin Zhou, Yasushi Orihashi, Joseph Pav, Vance Warren, Jeanne Mendell, Flavia Pizzagalli
Publikováno v:
The Journal of Clinical Pharmacology. 60:691-701
DS-1040, a novel low-molecular-weight inhibitor of activated thrombin-activatable fibrinolysis inhibitor, is under development for the treatment of thromboembolic diseases including venous thromboembolism and acute ischemic stroke. Here we describe t
Publikováno v:
Journal of Atmospheric Electricity. 38:53-66